{"id":691987,"date":"2022-10-04T10:33:04","date_gmt":"2022-10-04T14:33:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/"},"modified":"2022-10-04T10:33:04","modified_gmt":"2022-10-04T14:33:04","slug":"comera-life-sciences-expands-woburn-operations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/","title":{"rendered":"Comera Life Sciences Expands Woburn Operations"},"content":{"rendered":"
\n

\n Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event<\/em>\n <\/p>\n

WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc.<\/a> (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices.<\/p>\n

The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin and Massachusetts Biotechnology Council (MassBio) President and COO Kendalle Burlin O\u2019Connell. Comera currently has 12 employees. The increased footprint will allow the company to double its workforce in the coming years.<\/p>\n

\u201cThe expansion of our headquarters in Woburn is a milestone achievement as we continue to advance our internal pipeline and collaborations with some of the largest biopharmaceutical companies,\u201d said Jeffrey Hackman, Chairman and CEO of Comera. \u201cThis expansion is another step forward in supporting our continued growth as we execute on our long-term strategy to transform the lives of patients.\u201d<\/p>\n

Comera is developing a portfolio of proprietary injectable therapeutics \u2013 called subcutaneous (SQ) therapeutics \u2013 with the goal of making it possible for patients to administer medications that historically have been administered only by intravenous (IV) infusion. The company applies its team\u2019s deep knowledge of formulation science and technology to transform essential biologic medicines from IV to SQ forms, which has the potential to spare patients long trips to a hospital or infusion center, where they may stay for hours to receive treatment.<\/p>\n

\u201cAccess to necessary and lifesaving medications is a huge barrier for many in our commonwealth,\u201d said Friedman, Senate Chair of the Joint Committee on Health Care Financing. \u201cThe work of Comera Life Sciences seeks to directly address this barrier by providing a more convenient and equitable way to access these medications. I am pleased to have Comera continue this important work in Woburn and Massachusetts.\u201d<\/p>\n

\u201cI am thrilled to see Comera expanding its footprint here and continuing to develop biologic medicines in our city,\u201d said Haggerty. \u201cLife science firms see the benefits of locating and growing in Woburn, and I look forward to seeing what the future holds for Comera as the firm grows and increases its workforce in our community.\u201d<\/p>\n

\u201cAs the life sciences industry in Massachusetts continues to regionalize to places outside of Boston and Cambridge like Woburn, it makes careers available to new pools of talent and brings economic development to new cities and towns that are BioReady,\u201d said Burlin O\u2019Connell. \u201cI am pleased to celebrate with our MassBio member Comera as they reach this milestone in their growth and continue to seek to deliver comfort and accessibility to patients.\u201d<\/p>\n

The expansion is the latest milestone achieved by Comera this year. The company made its debut as a publicly traded company on the Nasdaq index in May.<\/p>\n

\n About Comera Life Sciences<\/strong>\n <\/p>\n

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.<\/p>\n

To learn more about the Comera Life Sciences, visit comeralifesciences.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the federal securities laws including statements regarding our ability to execute on our business strategy and our ability to access the $15 million in proceeds under the purchase agreement, or to exercise the option for an additional $15 million, due to the limitations contained in the purchase agreement. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: risks that the limitations in the purchase agreement will limit our sales and\/or prevent us to exercise our option or that we will need to seek stockholder approval, which we may not be able to obtain, to remove such limitations; that the recently completed business combination disrupts the Company\u2019s current plans and ability to retain its employees; the Company\u2019s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company\u2019s business; the price of the Company\u2019s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company\u2019s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company\u2019s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Current Report on Form 8-K filed with the SEC on May 25, 2022 under \u201cRisk Factors\u201d and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of Comera\u2019s Current Report on Form 8-K filed with the SEC on May 25, 2022 and other documents filed by Comera from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

\n Comera Investor<\/strong>:
John Woolford
ICR Westwicke
John.Woolford@westwicke.com<\/a><\/p>\n

\n Comera Press:<\/strong>
\n
Greg Turner
Ball Consulting Group, LLC
greg@ballcg.com<\/a>
617-243-9950<\/p>\n

Karen Chase
ICR Westwicke
Karen.Chase@westwicke.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices. The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin … <\/p>\n

Continue reading “Comera Life Sciences Expands Woburn Operations”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691987","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nComera Life Sciences Expands Woburn Operations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comera Life Sciences Expands Woburn Operations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices. The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin … Continue reading "Comera Life Sciences Expands Woburn Operations"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-04T14:33:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Comera Life Sciences Expands Woburn Operations\",\"datePublished\":\"2022-10-04T14:33:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/\"},\"wordCount\":1272,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/\",\"name\":\"Comera Life Sciences Expands Woburn Operations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=\",\"datePublished\":\"2022-10-04T14:33:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/comera-life-sciences-expands-woburn-operations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comera Life Sciences Expands Woburn Operations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comera Life Sciences Expands Woburn Operations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/","og_locale":"en_US","og_type":"article","og_title":"Comera Life Sciences Expands Woburn Operations - Market Newsdesk","og_description":"Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices. The Comera team was joined by state and local officials and members of the biotech industry, including Massachusetts State Senator Cindy F. Friedman, Massachusetts State Representative Richard M. Haggerty, Woburn Mayor Scott Galvin … Continue reading \"Comera Life Sciences Expands Woburn Operations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-04T14:33:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Comera Life Sciences Expands Woburn Operations","datePublished":"2022-10-04T14:33:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/"},"wordCount":1272,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/","name":"Comera Life Sciences Expands Woburn Operations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=","datePublished":"2022-10-04T14:33:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1ODA2MyM1MTg0OTAxIzIyNDcyODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/comera-life-sciences-expands-woburn-operations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Comera Life Sciences Expands Woburn Operations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691987"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691987\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}